close
Add to watchlist
ULURU Inc (ULU)
Uluru Inc., a pharmaceutical company, engages in the research, development, and commercialization of wound management, plastic surgery, and oral care products worldwide. The company's products are based on patented Nanoflex and OraDisc drug delivery technologies. Its products include Altrazeal, a transforming powder dressing for the treatment of various wounds, such as partial thickness burns, donor sites, and abrasions, as well as surgical, acute, and chronic wounds; Aphthasol and Aptheal for the treatment of canker sores; Residerm A gel-Zindaclin for the treatment of acne; OraDisc A for the treatment of oral conditions, which rely upon the use of medications formulated as gels and pastes that are applied to lesions in the mouth; and OraDisc B for the treatment and management of oral pain. The company has a license agreement with ProStrakan Ltd. for the manufacture, sale, and marketing of zinc clindamycin. Uluru is based in Addison, Texas.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 0.29 |
| Volume | 197091 |
| Volume Avg | 172616 |
| 52 Week High | 1.65 |
| 52 Week Low | 0.18 |
| PE | N/A |
| PE (group average) | N/A |
| EPS Year | -0.61 |
| EPS change Q/Q | 100% |
| EPS change Q/Q Yr ago | -50% |
| EPS change Q/Q next Q est | 100% |
| EPS change Y/Y | -100% |
| REV change Q/Q | -90% |
| REV change Q/Q Yr ago | -50% |
| EPS next Q est | 0.00 |
| EPS next Y est | 0.00 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |